GlassScriptPhysician profile
Rebecca Crenshaw
NPI 1205899622
$7,692.76
in general payments reported to CMS, 2019-2025
38 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $475 · 2021: $1,539 · 2022: $593 · 2023: $1,437 · 2024: $1,958 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,389 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.88 |
| Education | $111.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,483.67 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $803.85 | 2021-2024 | Qulipta, Ubrelvy |
| Genzyme Corporation | $550.45 | 2021-2024 | |
| Ucb, INC. | $457.14 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $378.28 | 2019-2025 | Ultomiris |
| Tg Therapeutics, INC. | $335.36 | 2023-2025 | |
| Emd Serono, INC. | $303.87 | 2020-2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $302.57 | 2024-2025 | Zeposia |
| Biogen, INC. | $261.41 | 2020-2025 | Vumerity, Tysabri |
| Argenx US, INC. | $254.87 | 2023-2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $238.72 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $233.59 | 2021 | |
| Horizon Therapeutics Plc | $203.32 | 2022-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $197.74 | 2019-2021 | |
| Pfizer INC. | $196.26 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $180.69 | 2019-2024 | Uplizna |
| Eisai INC. | $177.70 | 2024-2025 | |
| Kyowa Kirin, INC. | $173.61 | 2019-2022 | |
| Allergan, INC. | $158.14 | 2020 | |
| Upsher-Smith Laboratories LLC | $140.32 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $116.64 | 2021 | |
| Sk Life Science, INC. | $86.73 | 2020-2024 | Xcopri |
| Lundbeck LLC | $71.39 | 2020-2022 | |
| Lilly USA, LLC | $67.70 | 2019-2021 | |
| Acorda Therapeutics, INC | $53.68 | 2021 | |
| Livanova USA, INC. | $44.13 | 2022 | |
| Neurocrine Biosciences, INC. | $34.60 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.97 | 2019 | |
| Ge Healthcare | $23.75 | 2021 | |
| Mdd US Operations, LLC | $22.40 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.49 | 2020 | |
| Impel Pharmaceuticals INC. | $14.81 | 2022 | |
| Acadia Pharmaceuticals INC | $14.05 | 2021 | |
| Aucta Pharmaceuticals, INC. | $13.97 | 2025 | Motpoly Xr |
| Amarin Pharma, INC. | $12.99 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.89 | 2022 | |
| Novo Nordisk INC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.